Vet Comp Oncol. 2021 Sep 2. doi: 10.1111/vco.12770. Online ahead of print.
ABSTRACT
Radioactive iodine (131 I) has previously been reported to prolong survival in dogs with thyroid carcinoma. This study aimed to describe tumour response and progression-free interval (PFI) in dogs with thyroid carcinomas treated with 131 I. Secondary aims were to describe overall survival time (OST) and prognostic factors. A bi-institutional retrospective review of records iden tified 66 dogs with thyroid carcinoma treated with 131 I from January 2010-April 2020. Response was described using RECIST, or a subjective response assessment where specific tumour measurements were not available. Forty-eight dogs (72.7%) were treatment-naïve and 18 dogs (27.3%) had received prior therapy at the time of 131 I treatment. Objective responses were available for 34 dogs and subjective responses for 58 dogs. The overall response rate (ORR) was 35.3% (4 complete and 8 partial responses). Improvement of clinical signs was seen in 76.2% of dogs (32/42). Kaplan-Meier-estimated median PFI (95%CI) was 301 (217-578) days and OST (95%CI) was 564 (421-865) days. Prior therapy was associated with a lower hazard for progression (HR 0.260 95%CI 0.123-0.548, P=0.0004). Treatment of thyroid carcinoma using 131 I can effectively alleviate clinical signs and reduce disease burden in a proportion of dogs. This article is protected by copyright. All righ ts reserved.
PMID:34476889 | DOI:10.1111/vco.12770
No comments:
Post a Comment